Painful diabetic neuropathy affects approximately one-quarter of people with diabetes.
A phase 2 clinical trial examined the efficacy of treating painful diabetic neuropathy (PDN) with filorexant, an orexin receptor antagonist.
Researchers assessed whether neurolysis could alleviate pain associated with diabetic neuropathy.
A systematic literature review evaluated the effect of pharmacologic treatments of diabetic peripheral neuropathy on patients' pain and QOL.
The ADA updated recommendations on prevention methods and pain management for 2 forms of diabetic neuropathy.
Cumulative probability of proliferative diabetic retinopathy worsening was 42% in the panretinal photocoagulation group compared with 34% in the ranibizumab group.
Often underreported and undertreated, outcomes can be improved in this condition with appropriate screening and diagnosis.
For patients with moderate to severe diabetic peripheral neuropathic pain (DPNP), transdermal buprenorphine is effective for reducing pain, but is associated with adverse events.
Among women with type 1 diabetes there are increased odds of female sexual dysfunction and urinary incontinence associated with specific measures of cardiovascular autonomic neuropathy.
While there was no overall improvement, treatment with long-acting C-peptide improved vibration perception threshold.
One of the key contributors to peripheral nerve disease in patients with diabetes is the central nervous system.
Amputations among diabetes patients have declined as a result of improved diabetes health care.
Identifying foot problems early in diabetes can prevent serious and extensive complications.
There was a dose-dependent reduction in pain with inhaled cannabis in trial of 16 patients.
A plasmid containing two human hepatocyte growth factor isoforms may improve quality of life for patients with painful diabetic neuropathy.
Early intervention is essential to treating neuropathy in those with prediabetes.
Those who followed a vegan diet lost average of 15 lb and had improved blood flow to feet.
Concomitant use of these medications may result in B12 deficiency-induced neuropathy.
Aerobic exercise intervention doesn't appear to change pain severity measures.
Meta-analysis of two studies shows clinically significant improvement of "minimum change in pain."
Patients with diabetic peripheral neuropathy have a greater maximum and range of separations of center of mass from center of pressure.
A patient diagnosed with type 2 diabetes, hypertension, hyperlipidemia presents to the foot clinic after 1 month of swelling, redness, and warmth in the left foot.
Median neuropathy at the wrist could be an early indicator of diabetic polyneuropathy.
Certain factors contributing to unsteadiness may increase the risk for falls during stair climbing in patients with diabetic neuropathy.
Spinal cord stimulation successfully treated painful diabetic peripheral neuropathy in 59% of patients.
Patients with diabetic peripheral neuropathy may be at an increased risk for falling while climbing or descending stairs.
Statins may help prevent microvascular complications, such as neuropathy, retinopathy and gangrene of the foot, associated with diabetes.
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Nivolumab Associated With Thyroiditis in Patients With Cancer
- Gender-Related Association Between Physical Activity, Psychological Status in T2D
- Adverse Neurodevelopmental and Mental Health Outcomes in PCOS
- HbA1c Variability Predicts All-Cause Mortality in Type 2 Diabetes
- Choroidal Thickness Changes in Patients With Untreated Diabetes
- Pre-Pregnancy Fitness Lowers Gestational Diabetes Risk